US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could Be Next
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
AstraZeneca Updates Share Voting Rights
CytoSorbents Spikes on FDA Submission for DrugSorb-ATR
CytoSorbents Has Submitted Its DrugSorb-ATR Medical Device De Novo Marketing Application To The FDA, To Reduce Severity Of Perioperative Bleeding In Patients On Ticagrelor (Brilinta, AstraZeneca) Undergoing Coronary Artery Bypass Graft Surgery
ENHERTU (Fam-trastuzumab Deruxtecan-nxki) Granted Priority Review in the US for Patients With HER2-low or HER2-ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy